NCT02168946 - Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 21, 2017

Study Completion Date

July 21, 2017

Conditions

Urinary Tract Infection ComplicatedAcute PyelonephritisHospital Acquired Bacterial PneumoniaVentilator-associated Bacterial PneumoniaBacteremiaAbdominal Infection

Interventions

DRUG

Vabomere

Vabomere for IV injection, administered as a 2 g/2 g dose

DRUG

Best Available Therapy

Antibiotic(s) chosen by Investigator

Trial Locations (50)

0

Bogotá

4

Medellín

5016

Córdoba

5500

Mendoza

10032

New York

10467

The Bronx

11355

Flushing

11527

Athens

12462

Athens

14215

Buffalo

15213

Pittsburgh

16132

Genova

19104

Philadelphia

22908

Charlottesville

27710

Durham

28207

Charlotte

30912

Augusta

31096

Haifa

33100

Udine

33606

Tampa

40138

Bologna

44106

Cleveland

46202

Indianapolis

48073

Royal Oak

48201

Detroit

49100

Petah Tikva

50134

Florence

52621

Ramat Gan

54636

Thessaloniki

56124

Pisa

60201

Evanston

60611

Chicago

60612

Chicago

64239

Tel Aviv

06102

Hartford

08901

New Brunswick

C1405CNF

Buenos Aires

B1900AXI

La Plata

05652-900

São José do Rio Preto

São Paulo

30150-221

Belo Horizonte

81050-000

Curitiba

90035-903

Porto Alegre

14048-900

São Paulo

SP

São Paulo

Unknown

Barranquilla

106 76

Athens

00161

Rome

M23 9LT

Manchester

MI39WL

Manchester

All Listed Sponsors

collaborator

Department of Health and Human Services

FED

lead

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

INDUSTRY